CDK2 degrader 8 is a novel bifunctional protein degrader (PROTAC) developed based on patent WO 2025/181261, featuring Cyclopropyl and 1,3,4-Oxadiazole scaffolds. This compound facilitates the formation of a ternary complex between CDK2 and an E3 ubiquitin ligase, mediating the selective ubiquitination and subsequent proteasomal degradation of the target protein. In experimental models, it effectively blocks tumor cell cycle progression by depleting CDK2 levels, thereby demonstrating potent anti-proliferative activity.